Alza Corporation, DE, USA clinical trials
Acquired by Johnson & Johnson, Jun 22, 2001 · source ↗
The registry lists 37 studies whose lead sponsor is Alza Corporation, DE, USA. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 3, 2025.
Before and after it joined Johnson & Johnson
- First submitted before Alza Corporation, DE, USA became part of Johnson & Johnson
- 0
- First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- 37
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Alza Corporation, DE, USA37 studies
Something wrong with this grouping? Tell us on the Johnson & Johnson page.
Studies
Recruiting first, then most recently updated. Showing 37 of 37. All Johnson & Johnson studies →
- Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive BladderCompletedNCT00293839Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic PainCompletedNCT00410878Phase 1
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Prospective Safety Surveillance Study of Fentanyl Iontophoretic Transdermal System (40 Mcg)TerminatedNCT00665522
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With NarcolepsyCompletedNCT00424931Phase 2
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- An Evaluation of Safety of the Fentanyl Transdermal System for Management of Acute Post-Operative Pain in Pediatric PatientsWithdrawnNCT00666393Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With OsteoarthritisCompletedNCT00411164Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity DisorderCompletedNCT00269776Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity DisorderCompletedNCT00269815Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in ChildrenCompletedNCT00269789Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity DisorderCompletedNCT00269802Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Study to Evaluate the Safety of D-TRANS Fentanyl With Naltrexone in Adult Patients With Chronic Pain and Who Are Opioid TolerantCompletedNCT00650182Phase 2
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid EjaculationCompletedNCT01230762Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.CompletedNCT00269750Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- Clinical Use and Safety of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With CancerCompletedNCT00269763Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Scheduled Abdominal or Pelvic Surgery: The Fentanyl Transdermal System Versus the Morphine Intravenous PumpCompletedNCT00266539Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- Pharmacokinetics of Fentanyl Following Intravenous and Oral Routes of Administration in Healthy VolunteersCompletedNCT00714558Phase 1
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary IncontinenceCompletedNCT00269724Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary IncontinenceCompletedNCT00304499Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy VolunteersCompletedNCT00714584Phase 1
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.CompletedNCT00211107Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- Efficacy of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With CancerCompletedNCT00269737Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Total Hip Replacement: The E-TRANS Fentanyl Transdermal System Versus the Morphine Intravenous PumpCompletedNCT00264485Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque PsoriasisCompletedNCT00396422Phase 2
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature EjaculationCompletedNCT00211094Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.CompletedNCT00410540Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)CompletedNCT00410748Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mgCompletedNCT00398957Phase 1
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant PainCompletedNCT00410644Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)CompletedNCT00399048Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back PainCompletedNCT00411268Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- Bioequivalence Between Integrated E-TRANS (Fentanyl) System and Separated (Two-Part) E-TRANS (Fentanyl) SystemCompletedNCT00990418Phase 1
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer PainCompletedNCT00411034Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic PainCompletedNCT00410943Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mgCompletedNCT00399295Phase 1
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer PainCompletedNCT00410787Phase 3
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative PainCompletedNCT00411307Phase 2
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson
- A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back PainCompletedNCT00398788Phase 2
Sponsor listed in the registry: Alza Corporation, DE, USA · First submitted after Alza Corporation, DE, USA became part of Johnson & Johnson